Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

HIV-Specific T-Cell Therapy (DD HST-NEETs) for the Treatment of HIV-Infected Individuals on Antiretroviral Therapy following Donor Bone Marrow Transplantation, The alloRESIST Trial

Trial Status: administratively complete

This phase I trial investigates the safety, immune and virus responses of human immunodeficiency virus (HIV)-specific T-cell therapy (donor derived HIV-specific T-cells with non-escaped epitope targeting [DD HST-NEETs]) in HIV-infected individuals managing on anti-HIV medicines (antiretroviral therapy) following allogeneic (donor) bone marrow transplant. Allogeneic transplant in patients with HIV-1 infection presents some special risks and special opportunities. Donor T cells targeting HIV-1 may help protect the new donor bone marrow and immune system from HIV-1 infection.